The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms.
from RTT - Top Story https://ift.tt/pMVYLSi
via IFTTT
from RTT - Top Story https://ift.tt/pMVYLSi
via IFTTT
Comments
Post a Comment